Mangalam Drugs Valuation
| MANGALAM | 81.23 1.44 1.80% |
At this time, the firm appears to be overvalued. Mangalam Drugs And secures a last-minute Real Value of USD68.23 per share. The latest price of the firm is USD81.23. Our model forecasts the value of Mangalam Drugs And from analyzing the firm fundamentals such as Profit Margin of 0.01 %, return on equity of -0.0631, and Current Valuation of 1.92 B as well as examining its technical indicators and probability of bankruptcy.
Price Book 0.8535 | Enterprise Value 1.9 B | Enterprise Value Ebitda 5.613 | Price Sales 0.3708 | Enterprise Value Revenue 0.5565 |
Overvalued
Today
Please note that Mangalam Drugs' price fluctuation is very steady at this time. Calculation of the real value of Mangalam Drugs And is based on 3 months time horizon. Increasing Mangalam Drugs' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Mangalam Drugs is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Mangalam Stock. However, Mangalam Drugs' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 81.23 | Real 68.23 | Hype 82.84 | Naive 95.12 |
The real value of Mangalam Stock, also known as its intrinsic value, is the underlying worth of Mangalam Drugs And Company, which is reflected in its stock price. It is based on Mangalam Drugs' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Mangalam Drugs' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Mangalam Drugs And helps investors to forecast how Mangalam stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mangalam Drugs more accurately as focusing exclusively on Mangalam Drugs' fundamentals will not take into account other important factors: Mangalam Drugs Cash |
|
Mangalam Drugs Total Value Analysis
Mangalam Drugs And is now expected to have takeover price of 1.92 B with market capitalization of 1.69 B, debt of 1.07 B, and cash on hands of 917.4 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Mangalam Drugs fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.92 B | 1.69 B | 1.07 B | 917.4 M |
Mangalam Drugs Investor Information
About 55.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.85. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mangalam Drugs And recorded a loss per share of 4.03. The entity last dividend was issued on the 21st of December 2017. The firm had 10:1 split on the 29th of November 2016. Based on the key indicators related to Mangalam Drugs' liquidity, profitability, solvency, and operating efficiency, Mangalam Drugs And is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Mangalam Drugs Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Mangalam suggests not a very effective usage of assets in March.Mangalam Drugs Ownership Allocation
Mangalam Drugs And maintains a total of 15.83 Million outstanding shares. Mangalam Drugs And holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Mangalam Drugs Profitability Analysis
The company reported the revenue of 3.67 B. Net Loss for the year was (90.72 M) with profit before overhead, payroll, taxes, and interest of 1.17 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Mangalam Drugs' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Mangalam Drugs and how it compares across the competition.
About Mangalam Drugs Valuation
The stock valuation mechanism determines Mangalam Drugs' current worth on a weekly basis. Our valuation model uses a comparative analysis of Mangalam Drugs. We calculate exposure to Mangalam Drugs's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Mangalam Drugs's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 216.3 M | 205.5 M |
Complementary Tools for Mangalam Stock analysis
When running Mangalam Drugs' price analysis, check to measure Mangalam Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangalam Drugs is operating at the current time. Most of Mangalam Drugs' value examination focuses on studying past and present price action to predict the probability of Mangalam Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangalam Drugs' price. Additionally, you may evaluate how the addition of Mangalam Drugs to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |